Albuminar-5 Market Report 2026

Albuminar-5 Market Overview

• The Albuminar-5 market growth in the historic period has been driven by long standing use of albumin in hospitals, growth in surgical volumes • Market expansion is supported by expansion of emergency medicine infrastructure, rising aging population • Growth Driver: Rising Prevalence Of Genetic Disorders Drives Growth In The Market • Market Trend: ARTES Biotechnology And Basic Pharma Collaborate On Innovative Rhsa Production • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Albuminar-5 Market?

Albuminar-5 is a 5% human serum albumin solution used to restore blood volume and treat conditions such as hypoalbuminemia, shock, and burns. Derived from human plasma, it helps maintain osmotic pressure and fluid balance in critical care settings like surgery and trauma. The main types of formulations in albuminar-5 are human serum albumin, recombinant albumin, and bovine serum albumin. Human serum albumin is the most abundant protein in human blood plasma, playing a crucial role in maintaining oncotic pressure and transporting hormones, drugs, and other substances throughout the body. It can be identified by shock treatment, burns, and hypoalbuminemia, distributed through hospitals and clinics and retail and specialty pharmacies. End users include hospitals and clinics, the pharmaceutical and biotechnology industry, and research institutes.

What Is The Albuminar-5 Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of emergency medicine infrastructure, rising aging population, increasing incidence of chronic liver disease, demand for safe volume expanders, improved hospital access in developing regions. Major trends in the forecast period include continued use of isotonic albumin solutions, rising application in fluid resuscitation, growing demand in surgical and trauma settings, preference for safer plasma derived products, expansion of emergency care services.

What Are The Drivers Of The Albuminar-5 Market?

The rise in the prevalence of genetic disorders is expected to propel the albuminar-5 market going forward. A genetic disorder is a health condition caused by abnormalities in an individual's DNA, which can result from mutations in single or multiple genes, chromosomal changes, or a combination of genetic and environmental factors. The rising prevalence of genetic diseases is due to increased awareness and advancements in diagnostic technologies, as these enable earlier and more accurate detection of previously undiagnosed conditions. Albuminar-5 aids in managing genetic disorders by stabilizing blood volume, making it valuable for patients with hereditary conditions that cause low albumin levels or impaired fluid balance. It supports clinical care by restoring plasma protein concentration, reducing complications, and improving overall treatment outcomes. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023–2024, up from 2,681 patients in 2022–2023. Therefore, the growing availability of genetic testing is driving the expansion of the albuminar-5 industry. The rising healthcare expenditure is expected to propel the growth of the albuminar-5 market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure enhances albuminar-5 utilization by improving access to essential plasma-derived therapies, enabling hospitals and clinics to provide timely volume replacement and protein restoration for critical and chronic conditions. It supports investment in advanced treatment protocols, ensuring better patient outcomes and more efficient management of disorders requiring albumin supplementation. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the albuminar-5 industry.

Key Players In The Global Albuminar-5 Market

Major companies operating in the albuminar-5 market are Grifols S.A

Global Albuminar-5 Market Trends and Insights

Major companies operating in the albuminar-5 market are focusing on developing advanced therapeutic platforms, such as Reversible Helix Stabilizing Agents (RHSAs), to enhance the efficacy and stability of peptide-based pharmaceuticals. Reversible Helix Stabilizing Agents refer to a novel class of compounds that can temporarily stabilize the alpha-helical structure of peptides, a common but often unstable structural motif in drug development, thereby improving their drug-like properties. For instance, in May 2024, ARTES Biotechnology, a Germany-based company specializing in the development and transfer of recombinant cell lines, and Basic Pharma Life Science, an India-based company that manufactures pharmaceutical products, are on the verge of completing their collaborative project to produce recombinant human serum albumin (rHSA), with the first vials expected to be released this summer. This partnership leverages ARTES's expertise in microbial cell lines and protein production alongside Basic Pharma's pharmaceutical development capabilities. The rHSA, derived from Hansenula polymorpha yeast, aims to meet the needs of researchers in academia and industry for high-quality recombinant proteins.

What Defines the Albuminar-5 Market?

The albuminar-5 market consists of sales of products including buminate 5%, albunorm, and grifols albumin 5%. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Albuminar-5 Market Report 2026?

The albuminar-5 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the albuminar-5 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.